The clinical heterogeneity extends to the onset of the disease. In Met 30 amyloidosis, the onset is very variable among patients, ranging from the 3rd decade to the 7th decade or even later.
The meanage of onset of the clinical syndromein Portuguese patients is 32 for males, and 33 for females. Late onset may occur in some patients with symptomsnot apparent until the 6th or 7th decade. In Japanese patients, the meanage of onset is 32 years, and in the Swedish kindreds, the mean age of onset is 5.8. Gene dosage does not influence the onset, as homozygous individuals can be asymptomatic late in life. In TTRamyloidosis, it is clear that amyloid formation precedes the onset of clinical symptoms, however it is difficult to assess the timing relationship between the two events. At this point, the intervening factors in amyloidogenesis are largely unknown, but it is well known that there is a multifactorial process where possible hypotheses are not conclusive.
Age-of-onset and paternal transmission
Despite its autosomal dominant mode of inheritance, women are known to be less often affected with FAP-I, and to have a later onset than men. Sequeiros et al (3) studied the sex ratio and age-of-onset distribution in 1 ,072 Portuguese patients. There were 625 men and 447 womenaffected with a sex ratio of 1.45: 1. Amongall asymptomatic carriers of Met-30TTR, 334 were women and272 weremen (0.81 : 1). The sexratiofor 1, 678 (manifesting and non-manifesting) carriers was 1.15: 1. Mean age-of-onset was 34.8 in women and 31.7 years in men. This reflects different age-of-onset distributions, with overall later onset and less affected women. Sousa et al (4) further studied the consequences of age-ofonset of both sexes and that of the transmitting parent in Portuguese patients: 505 inherited the FAP gene from the mother, and 429 from the father. Men affected with FAP had, on average, an earlier onset than women.The meanage-ofonset was higher for children of transmitting fathers than of transmitting mothers, in any case, daughters have a higher mean age-of-onset. Thus, sons of affected mothers had the earliest onset (29.3), while daughters of affected fathers seemed to be the more "protected" (35.1 years) from the effects of the FAP gene. Both studies postulated a possible role of multifactorial inheritance of genetic modifiers, with a different threshold for eachsex.
Anticipation of age-of-onset in FAP-I
AmongPortuguese FAPpatients, no late-onset child (onset at or after age 52 years) has ever been found to descend from a classic-onset parent (onset before age 40). Late-onset patients, however, often have classic-onset children. Sousa et al (4) looked at the transmission of age-of-onset (from affected parents to their offspring) through pedigree analysis. The offspring of late-onset patients usually have an earlier onset than their parents. Sons of affected mothers (who, on average, had FAP 10.9 years earlier than their mothers), and daughters of affected fathers (who had onset 1.3 years later than their fathers) showed the extreme means. Drugge, et al (5) reported the results of a pedigree analysis on FAP-I in a Swedish family, using Swedish historical archives. The population studied included 239 patients: 109 patients were linked to five large pedigrees and 80 patients belonged to 30 smaller pedigrees or nuclear families. They found differences in mean ages of onset between the different pedigrees, although there was a considerable variation within the pedigrees. There was a tendency for later ages of onset amongolder generations than younger ones: descendants of affected mothers seemedto be more prone to an earlier age of onset than descendants of affected fathers. Furthermore, there seems to be a tendency for earlier ages of onset among patients with a carrier mother than a carrier father. Tashima, et al (6) tigation including DNAmethod. They also investigated the clinical syndromes and the age of onset of 20 deceased FAP patients from 1920 to 1960. They focused on the correlation between the age of onset and their birth year in calendar year. They found that the age of onset in Japanese FAPpatients was younger year by year. This tendency was more apparent in female FAP patients than in male patients. A typical family showed the tendency of anticipation in 3 generations. In their study, the tested numberof the FAPpatients was small, and showed only one pedigree. The accuracy of the information on the initial symptoms in deceased FAP patients seemed to be insufficient and not conclusive. Further study is necessary to confirm their data in other pedigrees of Japanese FAPpatients.
Pathogenesis
The pathogenesis ofFAP is still unknown. The reason for the different age of onset remains unclear, but this fact suggests that the amyloid formation in FAPmight not only be associated with the serum levels of variant TTRbut also with other unknown factors. In 1995, the Welfare Ministry of Japan reported that the average life expectancy in Japanese is 76.57 years in males and 82.98 years in females. Comparison of these figures with those at the beginning of the 20th century (1901) shows an increase of 33.3 years and 38.7 years, respectively. The Japanese nowhave the longest life expectancy in the world. The major reason for this marked increase seems to be, in addition to advances in medicine, improvementsin environment and nutrition resulting from economic growth in Japan. In Japan, many FAP patients live in Kumamoto and Nagano prefectures; good food, comfortable life style, and good sanitary conditions may have an affect on the onset of the disease. However, no crucial factor has as yet been found related to the pathogenesis of FAP. Anticipation of the age-of-onset in FAP awaits further study.
